KAEL–GemVax Release: Final Results From the Phase III TeloVac Trial in Pancreatic Cancer Presented at American Society of Clinical Oncology, Chicago, June 3rd 2013.
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
CHICAGO, Ill.--(BUSINESS WIRE)--The final results from TeloVac, a multi-centre Phase III trial of the GV1001 vaccine in advanced and metastatic pancreatic cancer were presented today at the annual ASCO meeting in Chicago. The TeloVac trial was sponsored by The Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, UK and was funded by Cancer Research UK. The trial was conducted through the Cancer Research UK Liverpool Clinical Trials Unit and supported by GemVax, a subsidiary of KAEL-GemVax. The trial recruited 1062 patients in 52 centres throughout the UK. There was no significant difference in overall survival between the groups that received the vaccine and the control group receiving chemotherapy. The trial also included an ambitious program of translational research, which is still undergoing evaluation. Initial results indicate that the vaccine resulted in a significant anti-inflammatory response that correlates well with new research being conducted by the parent company, Kael-GemVax. Additionally, two possible biomarkers for an increased survival in response to the vaccine in a subgroup of patients were identified.
Help employers find you! Check out all the jobs and post your resume.
CHICAGO, Ill.--(BUSINESS WIRE)--The final results from TeloVac, a multi-centre Phase III trial of the GV1001 vaccine in advanced and metastatic pancreatic cancer were presented today at the annual ASCO meeting in Chicago. The TeloVac trial was sponsored by The Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, UK and was funded by Cancer Research UK. The trial was conducted through the Cancer Research UK Liverpool Clinical Trials Unit and supported by GemVax, a subsidiary of KAEL-GemVax. The trial recruited 1062 patients in 52 centres throughout the UK. There was no significant difference in overall survival between the groups that received the vaccine and the control group receiving chemotherapy. The trial also included an ambitious program of translational research, which is still undergoing evaluation. Initial results indicate that the vaccine resulted in a significant anti-inflammatory response that correlates well with new research being conducted by the parent company, Kael-GemVax. Additionally, two possible biomarkers for an increased survival in response to the vaccine in a subgroup of patients were identified.
Help employers find you! Check out all the jobs and post your resume.